Related Experiment Video
Updated: Mar 8, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders
Paula Barreras1, Maureen A Mealy1, Carlos A Pardo1
1Department of Neurology & Division of Neuroimmunology and Neuroinfectious Disorders, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Johns Hopkins Transverse Myelitis Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Objectives:
Tumor necrosis factor-alpha inhibitors (TNFα-I) are biological agents used in the treatment of rheumatologic disorders. TNFα-I have been associated with demyelinating disorders mimicking multiple sclerosis. The goal of this report is to illustrate cases of myelopathy which developed during the use of TNFα-I.
Methods:
We describe the clinical, neuroimaging and laboratory features of 4 cases of myelopathy associated with TNFα-I.
Results:
The mean period of TNFα-I exposure was 27 [12-36] months. Three of the four patients exhibited active inflammatory myelopathy as the spinal cord MRI lesions enhanced with gadolinium and CSF pleocytosis or oligoclonal bands were present. All patients had normal brain MRIs at the time of presentation.
Conclusions:
TNFα-I may play a role in the development of myelopathies in absence of brain involvement or other features of demyelinating disease. TNFα-I associated myelopathy should be considered in patients with history of treatment with TNFα-I who exhibit symptoms of myelopathy.
More Related Videos
16:07Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
07:17Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents